» Articles » PMID: 37995336

Vascularized Brain Assembloids With Enhanced Cellular Complexity Provide Insights Into the Cellular Deficits of Tauopathy

Overview
Journal Stem Cells
Date 2023 Nov 23
PMID 37995336
Authors
Affiliations
Soon will be listed here.
Abstract

Advanced technologies have enabled the engineering of self-organized 3-dimensional (3D) cellular structures from human induced pluripotent stem cells (hiPSCs), namely organoids, which recapitulate some key features of tissue development and functions of the human central nervous system (CNS). While hiPSC-derived 3D CNS organoids hold promise in providing a human-specific platform for studying CNS development and diseases, most of them do not incorporate the full range of implicated cell types, including vascular cell components and microglia, limiting their ability to accurately recreate the CNS environment and their utility in the study of certain aspects of the disease. Here we have developed a novel approach, called vascularized brain assembloids, for constructing hiPSC-derived 3D CNS structures with a higher level of cellular complexity. This is achieved by integrating forebrain organoids with common myeloid progenitors and phenotypically stabilized human umbilical vein endothelial cells (VeraVecs), which can be cultured and expanded in serum-free conditions. Compared with organoids, these assembloids exhibited enhanced neuroepithelial proliferation, advanced astrocytic maturation, and increased synapse numbers. Strikingly, the assembloids derived from hiPSCs harboring the tauP301S mutation exhibited increased levels of total tau and phosphorylated tau, along with a higher proportion of rod-like microglia-like cells and enhanced astrocytic activation, when compared to the assembloids derived from isogenic hiPSCs. Additionally, the tauP301S assembloids showed an altered profile of neuroinflammatory cytokines. This innovative assembloid technology serves as a compelling proof-of-concept model, opening new avenues for unraveling the intricate complexities of the human brain and accelerating progress in the development of effective treatments for neurological disorders.

Citing Articles

Two- and Three-Dimensional In Vitro Models of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Applications.

Solana-Manrique C, Sanchez-Perez A, Paricio N, Munoz-Descalzo S Int J Mol Sci. 2025; 26(2).

PMID: 39859333 PMC: 11766061. DOI: 10.3390/ijms26020620.


Neuronal Circuit Dysfunction in Amyotrophic Lateral Sclerosis.

Salzinger A, Ramesh V, Das Sharma S, Chandran S, Selvaraj B Cells. 2024; 13(10.

PMID: 38786016 PMC: 11120636. DOI: 10.3390/cells13100792.


Brain organoid protocols and limitations.

Zhao H, Haddad G Front Cell Neurosci. 2024; 18:1351734.

PMID: 38572070 PMC: 10987830. DOI: 10.3389/fncel.2024.1351734.

References
1.
Wang C, Fan L, Khawaja R, Liu B, Zhan L, Kodama L . Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy. Nat Commun. 2022; 13(1):1969. PMC: 9005658. DOI: 10.1038/s41467-022-29552-6. View

2.
Mills J, Paluru P, Weiss M, Gadue P, French D . Hematopoietic differentiation of pluripotent stem cells in culture. Methods Mol Biol. 2014; 1185:181-94. DOI: 10.1007/978-1-4939-1133-2_12. View

3.
Michalicova A, Majerova P, Kovac A . Tau Protein and Its Role in Blood-Brain Barrier Dysfunction. Front Mol Neurosci. 2020; 13:570045. PMC: 7554615. DOI: 10.3389/fnmol.2020.570045. View

4.
Hopp S, Lin Y, Oakley D, Roe A, DeVos S, Hanlon D . The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease. J Neuroinflammation. 2018; 15(1):269. PMC: 6145371. DOI: 10.1186/s12974-018-1309-z. View

5.
Hong Y, Dong X, Chang L, Xie C, Chang M, Aguilar J . Microglia-containing cerebral organoids derived from induced pluripotent stem cells for the study of neurological diseases. iScience. 2023; 26(3):106267. PMC: 10014280. DOI: 10.1016/j.isci.2023.106267. View